Truist raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $36 from $30 and keeps a Buy rating on the shares. The company’s Q3 results are “impressive” and represent the relentless pursuit of LEMS patient identification that is driving continued growth of Firdapse six years after launch, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals Reports Strong Q3 2024 Earnings
- Closing Bell Movers: AppLoving up 29% after Q3 earnings beat
- Catalyst Pharmaceuticals reports Q3 non-GAAP EPS 57c, consensus 30c
- Catalyst Pharmaceuticals sees FY24 revenue $475M-$485M, consensus $473.67M
- CPRX Upcoming Earnings Report: What to Expect?